While stories of private equity firms running amok in health care are easy to find, new research paints a more nuanced picture.
Federal Policy
Posted inCost of Care
Surprise! Plans To Resolve High Medical Bills Are Still a Mess
Patients are now mostly protected from surprise bills, but doctors and insurers are still fighting over prices.
Posted inCost of Care
Sen. Bill Cassidy Wrestles with a $500 Billion Health Care Problem
Tradeoffs talks with Sen. Bill Cassidy about a new bipartisan effort to improve care for some of the country’s poorest, sickest patients.
Posted inHealth Law
How Pushing Hospitals to Give Away More Free Care Could Backfire
Some lawmakers want nonprofit hospitals to give away more free care. But experts warn that could wind up being worse for patients.
Posted inHealth Equity
Tradeoffs LIVE! Rooting Out Racial Bias in Health Care AI
A live conversation between a top federal health official and a health care executive about working together to keep AI from exacerbating racial bias in health care.
Posted inPublic Health
More Hospitals Move to Confront Medical Errors Head On
A growing number of hospitals are adopting programs to discuss and fix medical errors.
Posted inCost of Care
Can the U.S. Put an End to Surprise Ambulance Bills?
Congress banned most surprise medical bills back in 2020, with one major exception: ambulance rides. Can lawmakers find a fix?
Posted inInsurance
Could Medicaid Coverage Losses Dampen Voter Turnout?
Guest author Gabriella Aboulafia shares a study from Tennessee that could foreshadow how recent Medicaid coverage losses might affect upcoming elections.
Posted inInsurance
The 12 Million People Lost in a Maze of Medicare and Medicaid
Many of America’s poorest and sickest patients are stuck navigating two separate insurance programs — Medicare and Medicaid — to get the care they need.
Posted inCost of Care
How Patents Help Keep Obesity Drug Prices Sky-High
A recent JAMA study sheds light on how the manufacturers of a class of popular weight-loss drugs have avoided competition from more affordable generics.